Crossmark

Cost-effectiveness analysis of tislelizumab plus chemotherapy versus standard chemotherapy in first-line treatment for extensive-stage small cell lung cancer: perspectives from the United States and China

Crossref DOI link: https://doi.org/10.1007/s11096-024-01802-1

Published Online: 2024-09-14

Published Print: 2024-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Lang, Wenwang https://orcid.org/0009-0007-3583-9518
Ai, Qi

He, Yulong

Pan, Yufei

Jiang, Qinling

Ouyang, Ming

Sun, Tianshou
Funding

Funding for this research was provided by:

Drug clinical comprehensive evaluation project of Health Commission of Guangxi Zhuang Autonomous Region (YPPJ014)
License Information

Text and Data Mining valid from 2024-09-14

Version of Record valid from 2024-09-14
More Information

Article History

Received: 20 May 2024

Accepted: 3 September 2024

First Online: 14 September 2024

Conflicts of interest

: The authors declare that they have no conflicts of interest.

Document is current

Any future updates will be listed below